News - Heplisav

Filter

Current filters:

Heplisav

Popular Filters

Dynavax withdraws European MAA for Heplisav

18-02-2014

US biotech firm Dynavax Technologies says it has withdrawn the European Marketing Authorization Application…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Modest growth expected for hepatitis B vaccine market

Modest growth expected for hepatitis B vaccine market

12-02-2014

The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming…

Anti-viralsDynavax TechnologiesHeplisavHexyonMarkets & MarketingPharmaceuticalSanofiSanofi Pasteur MSDVaccines

FDA delays approval of Dynavax' Heplisav, issuing CRL

26-02-2013

Dynavax Technologies ( Nasdaq: DVAX) saw its shares plunge as much as 38% to $1.84 in pre-market trading…

Anti-viralsBiotechnologyDynavax TechnologiesHeplisavNorth AmericaRegulationVaccines

EMA accepts Dynavax' filing for hep B drug Heplisav

23-08-2012

US biotech firm Dynavax Technologies (Nasdaq: DVAX) revealed yesterday that the European Medicines Agency…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Back to top